文献速递糖尿病肥胖与代谢综合征

间歇性禁食在接受胰岛素治疗的2型糖尿病患者中的有效性与安全性(INTERFAST-2)——一项随机对照试验

Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

研究将46例接受胰岛素治疗的2型糖尿病患者随机分为间歇性禁食组(每周3个非连续禁食日)或对照组,干预12周。间歇性禁食组HbA1c较对照组显著降低(-7.3 ± 12.0 mmol/mol vs 0.1 ± 6.1 mmol/mol,P = 0.012),复合终点(体重下降≥2%、胰岛素剂量减少≥10%、HbA1c降低≥3 mmol/mol)在间歇性禁食组有8人达成而对照组无人达成(P < 0.001),未发生严重低血糖。作者认为间歇性禁食是改善血糖控制、减少每日胰岛素总剂量和体重的安全可行的饮食选择。

要点

  • 间歇性禁食组HbA1c较对照组显著降低(-7.3 ± 12.0 mmol/mol vs 0.1 ± 6.1 mmol/mol,P = 0.012)。
  • 复合终点在间歇性禁食组8人达成、对照组无人达成(P < 0.001)。
  • 未发生严重低血糖,间歇性禁食为安全可行的饮食选择。

核心结论

  • 间歇性禁食是改善血糖控制、减少每日胰岛素总剂量和体重的安全可行的饮食选择。

研究设计与样本

  • 随机对照试验,46例接受胰岛素治疗的2型糖尿病患者随机分为间歇性禁食组或对照组,干预12周,提供饮食咨询和连续血糖监测。
  • 共同主要终点为基线至12周HbA1c变化和复合终点(体重下降≥2%、胰岛素剂量减少≥10%、HbA1c降低≥3 mmol/mol)。

主要发现

  • 间歇性禁食组HbA1c降低-7.3 ± 12.0 mmol/mol,对照组为0.1 ± 6.1 mmol/mol,组间比较P = 0.012。
  • 复合终点在间歇性禁食组有8人达成,对照组无人达成(P < 0.001)。
  • 未发生严重低血糖。

关键数值与推荐

  • 复合终点定义为体重下降≥2%、胰岛素剂量减少≥10%且HbA1c降低≥3 mmol/mol。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. RESEARCH DESIGN AND METHODS: Forty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ≥2%, insulin dose reduction ≥10%, and HbA1c reduction ≥3 mmol/mol). RESULTS: The IF group showed a significant HbA1c reduction (-7.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P < 0.001). No severe hypoglycemia occurred. CONCLUSIONS: IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Obermayer A, Tripolt NJ, Pferschy PN, et al. Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial. Diabetes Care. 2023. PMID: 36508320. doi:10.2337/dc22-1622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。